United States Influenza Vaccines Market: Focus on Persons Vaccinated, Pricing, Production, Supply, Promising Influenza Vaccines, Clinical Trials, Regulatory, Reimbursement, Distribution Channel, Major Deals, Key Players, Recent Developments – Size, Share, Trends, Analysis, Demand, Opportunity, and Forecast, 2022 – 2030

February 2022 | 220 pages | ID: U9B0A0438C65EN
DPI Research

Abstracts

The United States Influenza Vaccines market size is expected to reach USD 7,007 million by 2030. It is expected to expand at a CAGR of 6.9% from 2021 to 2030.

This new market report offerings an wide-ranging study of the entire United States influenza vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States influenza vaccines market. The report also provides up-to-date market size data for the period 2015 - 2021 and an illustrative forecast to 2030 covering key market aspects like market value and volume for influenza vaccines.

This Newest and Comprehensive United States Influenza Vaccines Market Research Report 2022 Delivers:

• The United States Influenza Vaccines Market Size, Insights, Analysis and Forecast,2015-2030
• The United States Number of Persons Vaccinated with Influenza Vaccines and Forecast, 2015 - 2030
• Analyzes the United States Children Being Vaccinated with Influenza Vaccines and Forecast,2015 - 2030
• Analyzes the United States Adults Being Vaccinated with Influenza Vaccines and Forecast, 2015 - 2030
• Key Market Growth Drivers and Challenges of the United States Influenza Vaccines Market
• The United States Influenza Vaccines Pricing Analysis, Trends and Insights
• The United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
• The United States Influenza Vaccines Distribution and Demand Analysis (2010 - 2021)
• Examines the Effectiveness of the Influenza Vaccines in the United States (2004 – 2021)
• Thoroughly Evaluates Rapid Diagnostic Testing for the Management of Influenza
• Distribution Channel and Technique Detailed Insights of Influenza Vaccination in the United States
• Reimbursement Environment of the United States Influenza Vaccines Market
• Regulatory Framework of the United States Influenza Vaccines Market
• Major Deals and Agreement Activities in the Influenza Vaccines Market
• An Insightful Analysis of the Promising Influenza Vaccines in the Clinical Development
• Analyses the Most Recent Clinical Trials of the Influenza Vaccines between 2020 and 2021
• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Influenza Vaccines Market Value, and Recent Development
• An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

The Major and Emergent Market Players for the U.S Influenza Vaccines Market are Listed Below:

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Seqirus (CSL Limited)
• AstraZeneca
• Novavax
• BiondVax Pharmaceuticals Ltd.
• Medicago
• Moderna Inc
• Pneumagen
• Daiichi–Sankyo
• Altimmune
• FluGen
• Imutex
• Versatope Therapeutics, Inc
• EpiVax, Inc

Key Questions Answered by this Latest 2022 Report:

• What is the current scenario of the U.S. influenza vaccines market?
• What is the total market size and forecast (until 2030) for the U.S. influenza vaccines market?
• How many persons being vaccinated with influenza vaccines in the US during 2015 – 2027?
• How effective is influenza(flu) shot for 2021?
• What percentage of the United States do people get the flu vaccine?
• What are the key marketed influenza vaccines available in the United States?
• What are the major drivers of the United States influenza vaccines market?
• What are the major inhibitors of the United States influenza vaccines market?
• What is the reimbursement pattern in the United States influenza vaccines market?
• What is the regulatory framework in the United States influenza vaccines market?
• What are the major deals and agreement happenings in the United States influenza vaccines market?
• What are the upcoming influenza vaccines that will have a significant impact on the market in the future?
• Who are the top market players? What are their happenings, vaccine revenue, current developments, and scenarios?
• Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?
• How is the market predicted to develop in the future?

Contents

1. EXECUTIVE SUMMARY

2. UNITED STATES INFLUENZA VACCINES MARKET SIZE, INSIGHTS, ANALYSIS AND FORECASTS (2015 - 2030)

3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2015 - 2030)

3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines

4. KEY MARKET GROWTH DRIVERS AND CHALLENGES OF THE UNITED STATES INFLUENZA VACCINES MARKET

4.1 Market Drivers
4.2 Market Challenges

5. UNITED STATES INFLUENZA VACCINES PRICING ANALYSIS, TRENDS AND INSIGHTS

6. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES)

7. UNITED STATES INFLUENZA VACCINES DISTRIBUTION AND DEMAND ANALYSIS (2010 - 2021)

8. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES (2004 – 2021)

9. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA

10. DISTRIBUTION CHANNEL AND TECHNIQUE DETAILED INSIGHTS OF INFLUENZA VACCINATION IN THE UNITED STATES

11. REIMBURSEMENT ENVIRONMENT OF THE UNITED STATES INFLUENZA VACCINES MARKET

12. REGULATORY FRAMEWORK OF THE UNITED STATES INFLUENZA VACCINES MARKET

13. MAJOR DEALS AND AGREEMENT ACTIVITIES IN THE INFLUENZA VACCINES MARKET

13.1 Merger and Acquisitions
13.2 Collaboration Deals
13.3 Licensing Agreement
13.4 Exclusive Agreement
13.5 Distribution Agreement

14. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT

15. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY AND COUNTRY

15.1 Year 2021
15.2 Year 2020

16. KEY PLAYERS ANALYSIS

16.1 Sanofi Pasteur
  16.1.1 Business Overview
  16.1.2 Influenza Vaccines Portfolio
  16.1.3 Influenza Vaccines Sales Value Analysis
  16.1.4 Promising Influenza Vaccines in the Clinical Development
  16.1.5 Recent Development
16.2 GlaxoSmithKline (GSK)
  16.2.1 Business Overview
  16.2.2 Influenza Vaccines Portfolio
  16.2.3 Influenza Vaccines Sales Value Analysis
  16.2.4 Recent Development
16.3 Seqirus
  16.3.1 Business Overview
  16.3.2 Influenza Vaccines Portfolios
  16.3.3 Influenza Vaccines Sales Value Analysis
  16.3.4 Promising Influenza Vaccines in the Clinical Development
  16.3.5 Recent Development
16.4 AstraZeneca
  16.4.1 Business Overview
  16.4.2 Influenza Vaccines Portfolio
  16.4.3 Influenza Vaccines Sales Value Analysis
  16.4.4 Recent Development

17. EMERGING PLAYERS ANALYSIS

17.1 Novavax
  17.1.1 Business Overview
  17.1.2 Promising Influenza Vaccines in the Clinical Development
  17.1.3 Recent Development
17.2 BiondVax Pharmaceuticals Ltd.
  17.2.1 Business Overview
  17.2.2 Promising Influenza Vaccines in the Clinical Development
  17.2.3 Recent Development
17.3 Medicago
  17.3.1 Business Overview
  17.3.2 Promising Influenza Vaccines in the Clinical Development
  17.3.3 Recent Development
17.4 Moderna Inc
  17.4.1 Business Overview
  17.4.2 Promising Influenza Vaccines in the Clinical Development
  17.4.3 Recent Development
17.5 Pneumagen
  17.5.1 Business Overview
  17.5.2 Promising Influenza Vaccines in the Clinical Development
  17.5.3 Recent Development
17.6 Altimmune
  17.6.1 Business Overview
  17.6.2 Promising Influenza Vaccines in the Clinical Development
  17.6.3 Recent Development
17.7 Daiichi Sankyo
  17.7.1 Business Overview
  17.7.2 Promising Influenza Vaccines in the Clinical Development
  17.7.3 Recent Development
17.8 FluGen
  17.8.1 Business Overview
  17.8.2 Promising Influenza Vaccines in the Clinical Development
  17.8.3 Recent Development
17.9 Imutex
  17.9.1 Business Overview
  17.9.2 Promising Vaccines in the Clinical Development
  17.9.3 Recent Development
17.10 EpiVax
  17.10.1 Business Overview
  17.10.2 Promising Influenza Vaccines in the Clinical Development
  17.10.3 Recent Development
17.11 Versatope Therapeutics, Inc.
  17.11.1 Business Overview
  17.11.2 Promising Influenza Vaccines in the Clinical Development
  17.11.3 Recent Development

List Of Tables

LIST OF TABLES:

Table 5–1: United States Pediatric Influenza Vaccines Price, 2021 – 2022
Table 5–2: United States Adult Influenza Vaccines Price, 2021 – 2022
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2021 – 2022
Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2020 – 2021
Table 7–2: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–5: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–6: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–7: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2021
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 12–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 13–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 13–2: Collaboration Deal in the Influenza Vaccines Market
Table 13–3: Licensing Agreement in the Influenza Vaccines Market
Table 13–4: Exclusive Agreement in the Influenza Vaccines Market
Table 13–5: Distribution Agreement in the Influenza Vaccines Market
Table 14–1: BiondVax Pharmaceuticals Ltd. – Clinical Trials
Table 16–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 16–2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 17–1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 17–2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 17–3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 17–4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 17–5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 17–6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 17–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 17–8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 17–9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 12–10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 12–11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development

List Of Figures

LIST OF FIGURES:

Figure 2–1: United States Influenza Vaccines Market Size and Analysis (Million US$),2015 – 2021
Figure 2–2: United States Influenza Vaccines Market Size and Forecast (Million US$),2022 – 2030
Figure 3–1: United States Total Number of Individuals Vaccinated with Influenza Vaccines (Thousand), 2015 – 2021
Figure 3–2: United States Total Number of Individuals Vaccinated with Influenza Vaccines Forecast (Thousand), 2022 – 2030
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2015 – 2021
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2022 – 2030
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2015 – 2021
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2022 – 2030
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2021
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2019 - 2020
Figure 16–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2015 – 2021
Figure 16–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2022 – 2030
Figure 16–3: GSK Influenza Vaccines Net Sales Value (Million US$),2015 – 2021
Figure 16–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2022 – 2030
Figure 16–5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 – 2021
Figure 16–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2022 – 2030
Figure 16–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2015 – 2021
Figure 16–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2022 – 2030